Researchers from Shandong University reported on the preclinical characterization of A3B3C-1, a multifunctional agent for the treatment of Alzheimer’s disease (AD), taking into account its complex nature. With multiple processes involved in its pathogenesis, the exploration of multi-target drugs may fit to address the combination of pathological factors in AD.
Neuren Pharmaceuticals Ltd. plans to progress NNZ-2591 to phase III trials following positive top-line phase II results in children with Phelan-McDermid syndrome, a genetic neurodevelopmental disorder for which there are no approved treatments.
Neuroone Medical Technologies Corp. received U.S. FDA 510(k) clearance for its Onerf ablation system which is capable of both recording electrical activity and ablation of nervous tissue.
The KCNC1 gene encodes the voltage-gated potassium channel subunit KV3.1, and variants in this gene have been previously linked to developmental and epileptic encephalopathy (DEE).
Xalud Therapeutics Inc. has described conjugates comprising a sugar moiety covalently bonded to a DNA-interacting moiety through a linker reported to be useful for the treatment of pain, inflammation and autoimmune diseases, among others.
Cypralis Ltd. has divulged macrocyclic compounds acting as peptidyl-prolyl cis-trans isomerase A (PPIA; cyclophilin A; CYPA) and/or cyclophilin D inhibitors reported to be useful for the treatment of multiple sclerosis and epilepsy.
Researchers from Gilgamesh Pharmaceuticals Inc. and affiliated organizations have presented the discovery and preclinical evaluation of GM-3009, a novel noribogaine analogue being developed for the treatment of opioid use disorder (OUD).
The term cerebral small vessel disease (SVD) refers to the sum of all pathological processes affecting the small vessels of the brain. Although SVD has been recognized as a leading cause of age-related cognitive decline, its underlying mechanisms remain unknown. Moreover, therapeutic options for SVD patients are still limited, primarily because relevant disease models that can guide target identification and drug discovery are lacking.
Sound Wave Innovation Co. Ltd. seeks patent protection for a method of using an ultrasonic device which transmits non-converging ultrasonic energy to the brain for the treatment of dementia, including mild Alzheimer’s-type dementia and mild cognitive impairment.
RSS
